These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 29244162)

  • 41. Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation.
    Dressler C; Eisert L; Pham PA; Nast A
    J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1249-1260. PubMed ID: 30735612
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
    McInnes IB; Mease PJ; Ritchlin CT; Rahman P; Gottlieb AB; Kirkham B; Kajekar R; Delicha EM; Pricop L; Mpofu S
    Rheumatology (Oxford); 2017 Nov; 56(11):1993-2003. PubMed ID: 28968735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.
    Mahil SK; Ezejimofor MC; Exton LS; Manounah L; Burden AD; Coates LC; de Brito M; McGuire A; Murphy R; Owen CM; Parslew R; Woolf RT; Yiu ZZN; Uthman OA; Mohd Mustapa MF; Smith CH
    Br J Dermatol; 2020 Oct; 183(4):638-649. PubMed ID: 32562551
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treating to Target(s) With Interleukin-17 Inhibitors.
    Lynde CW; Beecker J; Dutz J; Flanagan C; Guenther LC; Gulliver W; Papp K; Rahman P; Sholter D; Searles GE
    J Cutan Med Surg; 2019; 23(2_suppl):3S-34S. PubMed ID: 30742778
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
    Canavan TN; Elmets CA; Cantrell WL; Evans JM; Elewski BE
    Am J Clin Dermatol; 2016 Feb; 17(1):33-47. PubMed ID: 26649440
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of biologics on fatigue in psoriatic arthritis: A systematic literature review with meta-analysis.
    Reygaerts T; Mitrovic S; Fautrel B; Gossec L
    Joint Bone Spine; 2018 Jul; 85(4):405-410. PubMed ID: 29452303
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review.
    Sondag M; Verhoeven F; Guillot X; Prati C; Wendling D
    Clin Rheumatol; 2019 Feb; 38(2):591-596. PubMed ID: 30328022
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment modifying factors of biologics for psoriatic arthritis: a systematic review and Bayesian meta-regression.
    Druyts E; Palmer JB; Balijepalli C; Chan K; Fazeli MS; Herrera V; Jansen JP; Park JJH; Kanters S; Reimold A
    Clin Exp Rheumatol; 2017; 35(4):681-688. PubMed ID: 28094756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis.
    Alfonso-Cristancho R; Armstrong N; Arjunji R; Riemsma R; Worthy G; Ganguly R; Kleijnen J
    Clin Rheumatol; 2017 Jan; 36(1):25-34. PubMed ID: 27726046
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain.
    Schweikert B; Malmberg C; Núñez M; Dilla T; Sapin C; Hartz S
    BMJ Open; 2020 Aug; 10(8):e032552. PubMed ID: 32792421
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients with active rheumatoid arthritis : A Bayesian network meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Z Rheumatol; 2018 Jun; 77(5):421-428. PubMed ID: 28324148
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of secukinumab in patients with psoriatic arthritis: A meta-analysis of different dosing regimens.
    Zhang KL; Hou SY; Wu D
    Clinics (Sao Paulo); 2021; 76():e2820. PubMed ID: 34614111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
    McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
    Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.
    Mease PJ; Gladman DD; Merola JF; Nash P; Grieve S; Laliman-Khara V; Willems D; Taieb V; Prickett AR; Coates LC
    Rheumatology (Oxford); 2024 Jul; 63(7):1779-1789. PubMed ID: 38218744
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
    Ritchlin CT; Helliwell PS; Boehncke WH; Soriano ER; Hsia EC; Kollmeier AP; Chakravarty SD; Zazzetti F; Subramanian RA; Xu XL; Zuraw QC; Sheng S; Jiang Y; Agarwal P; Zhou B; Zhuang Y; Shawi M; Karyekar CS; Deodhar A
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33568556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.